1. Characteristic 1: a T cell double activated antigen binding molecule, including (3) the first antigen binding residue, which is a fab molecule that can be specially added with CD3, It includes at least a series of amino acids in the heavy chain complementarity determining region, a light chain chlorinated paraffin selected from components of SEC 37, 38 and 39, and from components of SEC 32, 33 and 34.(iv) a second antigen-binding moiety capable of specifically binding to folate receptor 1 (FolR1). Claim 54: A bispecific antibody comprising a) a first antigen binding site that competes for binding to human FolR1 with a reference antibody comprising a heavy chain variable domain (VH) of SEQ ID No. 49 and a variable domain light chain SEQ ID No. 51； and b) a second antigen binding site that competes for binding to human CD3 with a reference antibody comprising a heavy chain variable domain (VH) of SEQ ID No. 36 and a light chain variable domain of SEQ ID No. 31 ,It's the surface plasmon resonance test to measure the league competition 113. Claim 101: an insulating polypeptide comprising the amino acid sequence of SEC number 274. 2. Claim 115: composition of drug type C1. Package two T-cell active binding antigen molecules in any one to 99 claims and a vehicle acceptable on a drug. 2. Claim 121: use of claim 119 or method of claim 120It's a cancer.Reivindicación 1: Una molécula de unión a antígeno biespecífica activadora de células T que comprende (iii) un primer resto de unión a antígeno que es una molécula Fab capaz de unirse específicamente a CD3, y que comprende al menos una secuencia de aminoácidos de región determinante de la complementariedad (CDR) de cadena pesada seleccionada entre el grupo que consiste en SEC ID Nº 37, SEC ID Nº 38 y SEC ID Nº 39 y al menos una CDR de cadena ligera seleccionada entre el grupo de SEC ID Nº 32, SEC ID Nº 33, SEC ID Nº 34； (iv) un segundo resto de unión a antígeno capaz de unirse específicamente al receptor 1 de folato (FolR
